Logo
x

Search

Subscribe Now

seizures

GW's Epidyolex (cannabidiol) Receives MHRA's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in UK

GW's Epidyolex (cannabidiol) Receives MHRA's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in...

  • August 11, 2021
GW Pharmaceuticals' Epidyolex (cannabidiol) Receives EC's Approval for the Treatment of Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals' Epidyolex (cannabidiol) Receives EC's Approval for the Treatment of Seizures Associated with Tuberous Sclerosi...

  • April 21, 2021
Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Caregivers- and Families at AAN 2021

Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Care...

  • April 19, 2021
PharmaShots Interview: Zogenix's Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

PharmaShots Interview: Zogenix's Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)

  • February 16, 2021
UCB Canada's Brivlera (brivaracetam) Receives Health Canada Approval to Treat Partial-Onset Seizures in Pediatric Epilepsy Patients

UCB Canada's Brivlera (brivaracetam) Receives Health Canada Approval to Treat Partial-Onset Seizures in Pediatric Epilepsy Patient...

  • July 30, 2020
Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome

Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome

  • June 26, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.